Short-term stock returns are largely driven by the perception of near-term earnings per share. Read more here.

Bailard Inc. drastically reduced its stake in Regeneron Pharmaceuticals, offloading 69.9% of its shares in the first quarter.

If you're looking for stocks that can make dramatic movements in a short time frame, the biotechnology space has what you ...

CWM LLC has more than doubled its stake in Regeneron Pharmaceuticals, snapping up an additional 2,007 shares to now hold a ...

Eylea's sales slump and pipeline setbacks have dragged REGN down 22.8% YTD, underperforming its peers and the S&P 500.

Regeneron’s shares (currently trading at $552.99) have posted a disappointing 18.9% loss, well below the S&P 500’s 4.5% gain.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Stay with Moneycontrol to get real time updates on US MARKET share price, top gainers, top losers and market insights.

The major stock market indexes were flat to slightly lower for the week, but right at highs despite big new Trump tariffs.

Stay with Moneycontrol to get real time updates on US MARKET share price, top gainers, top losers and market insights.

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...